Brian Skorney

Baird Analyst Says 'Don't 'Give Up' Yet On Gilead's Remdesivir

Aimmune Analyst Says Palforzia Launch Funding Secured With Nestle's $200M Investment

Aimmune Analysts Bullish On Strong Uptake Of Peanut Allergy Drug Palforzia

Aimmune Analyst Says Palforzia Launch Funding Secured With Nestle's $200M Investment

Aimmune Analysts Bullish On Strong Uptake Of Peanut Allergy Drug Palforzia

Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgrade

Gilead Falls On Uninspiring Q3 Print: 3 Analyst Takes

Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgrade

Gilead Falls On Uninspiring Q3 Print: 3 Analyst Takes

Biotech Stock On The Radar: Aimmune Awaits Adcom Test

Axovant Analyst Turns Bullish Ahead Of Q4 Gene Therapy Data Readouts

Brian Skorney Recent News

Analysts Laud Biogen's M&A Strategy Following Deal to Buy Gene Therapy Company Nightstar

Baird: Biogen A Buy On M&A Prospects, Underappreciated Franchises

Baird: Prospects For Proteostasis Therapeutics' PTI-428 Are Not Priced Into The Stock

Analyst: Regeneron Is Undervalued By The Street

Regeneron Pharmaceuticals Gains A Bull Ahead Of Earnings

Pipeline Bomb: Analysts Review Celgene's Crohn's Diseases Failure

Celgene's Pipeline In Question After GED Failure

Analyst Says Axovant's Bull Case Is Effectively Over

FDA Letter On Intercept Pharma Doesn't Include Black Box Warning Label...Yet

Expectations For Regeneron No Longer Realistic; Analyst Downgrades

Approval For Neurocrine's Ingrezza Was No Surprise, But Lack Of Warning Label A Big Advantage Over Teva

The Street Is Misreading Sarepta's Guidance

Gilead's 2017 Guidance Sank Shares To A New Bottom

Theravance Biopharma's Valuation Has Gotten A Little Carried Away

Sarepta's Deal With Summit Could Be More About European Eteplirsen Approval Expectations

Patent Trial And Appeal Board Hands Sarepta Another Big Win

Drug Trial Extension By FDA Doesn't Change Baird's Outlook On Sarepta

Is Biogen Becoming A Reasonable Target For Acquisition? Baird Says So

Baird: Gilead Set For Q1 EPS Miss, But Hep C Trends Still Good Long Term

Baird And Piper Jaffray Love Vertex: Here's Why

All-Star Analysts Discuss GoPro, Apple & Gilead Before They Make Headlines

Baird Comments On Achillion's Bullish Share Action

VRTX Well Positioned To Capture Initial Paradigm Shift In Hep C Therapy